2016-2020

• On November 26th, 2020, Longjin signed an agreement with the School of Pharmacy of Kunming Medical University and awarded as the Practice Teaching Base.
• Kunming Longjin Pharmaceutical Co., Ltd. was conferred with the achievement award “One of Top Ten Influential Enterprises in Yunnan” in December 2019.
• On December 25th, 2020, Kunming Longjin Pharmaceutical Co., Ltd. was selected as the "Vice President Unit of the Second Council of Yunnan Young Entrepreneurs Chamber of Commerce".
• “Longjin” brand erigeron breviscapus was conferred with the title “One of Top Ten Famous Medicinal Materials 2018” in Yunnan Province again in 2019.
• On December 22nd, 2020, Longjin Pharmaceutical was recognized as Kunming International (Foreign) Science and Technology Cooperation Base by Kunming Science and Technology Bureau.
• The holding subsidiary Jiangsu Longjin Kangyou Biomedical Technology Co., Ltd. was established in June 2019.
• On November 3rd, 2020, Longjin established School-Enterprise Cooperation Relationship with Yunnan University and signed to be awarded as the Student Employment and Entrepreneurship Practice Base.
• The company formally entered the High-Level Talent Innovation and Entrepreneurship Park of Yunnan Province in June 2019.
• In October 2020, Longjin completed the construction of cGMP Standard Solid Formulation Workshop and Innovated Pilot-scale Production Platform, and put into trial production on November 5th .
• Kunming Longjin Pharmaceutical Co., Ltd. increased the investment for Yunnan Muya Agricultural Technology Co., Ltd. to make overall arrangement in hemp in 2019.
• In September 2020, Longjin Pharmaceutical was awarded " Superior Intellectual Property Enterprise of Yunnan Province ".
• Breviscapine manufactured by us passed GRAS certification accepted by FDA in February 2019.
• In July 2020, Defibrase, one of the injection products of Longjin resumed production. In September 2020, the holding subsidiary Yunnan Longjin Pharmaceutical Sales Co., Ltd was established.
• “Longjin”brand erigeron breviscapus was conferred with the title “One of Top Ten Famous Medicinal Materials 2018” in Yunnan Province in 2018.
• In March 2020, Zhang Wei, the R&D leader of Longjin Pharmaceutical, was awarded the first batch of "Spring City Plan" Industrial Technology Leading Talents.
• Kunming Longjin Pharmaceutical Co., Ltd. was provided with the special fund support for the industrial development of Traditional Chinese Medicine decoction pieces by Yunnan Department of Industry and Information Technology in 2018
• In 2019, Longjin Pharmaceutical was listed as one of the annual top 100 Chinese traditional medicine enterprises.
• Longjin® freeze-dried breviscapine powder injection was included in the selected “ China Top 100 Massive Health Brands Program” in 2018.
• Kunming Longjin Pharmaceutical Co., Ltd. was included in the “Science and Technology Competitiveness Ranking List of Traditional Chinese Medicine Varieties 2018” in 2018.
• The new plant passed the GMP re-certification by CFDA in July 2018.
• Kunming Longjin Pharmaceutical Co., Ltd. established the holding subsidiary “Yunnan CAS Longjin Biotechnology Co., Ltd.” by cooperating with KUNMING INSTITUTE OF ZOOLOGY, CAS in January 2018.
• “Longjin brand freeze-dried breviscapine powder injection” was conferred with the famous brand title of Kunming City in December 2017.
• Kunming Longjin Pharmaceutical Co., Ltd. was conferred with the best facility management award 2017 by International Society of Pharmaceutical Engineers (ISPE) in 2017.
• Kunming Longjin Pharmaceutical was conferred with the honor certificate of “The 7th Kunming Mayor Quality Award” by Kunming Municipal People’s Government in 2017.
• Kunming Longjin Pharmaceutical was conferred with the honorary title “Yunnan Private Small Giant Enterprise” by Yunnan Department of Industry and Information Technology again on December 29, 2016.
• Kunming Longjin Pharmaceutical was selected as “Yunnan Manufacturing Individual Champion Cultivating Enterprise 2016” by Yunnan Industry and Information Technology Commission on December 26, 2016.
• Kunming Longjin Pharmaceutical developed the erigeron breviscapus new variety “Longjin No,1” with the content of breviscapine up to 0.03 in 2016.
• The standardized construction of breviscapine injection was regarded as the standardized project of traditional Chinese medicine by State Administration of Traditional Chinese Medicine of the People's Republic of China in 2016.
• Kunming Longjin Pharmaceutical formally launched the smart manufacturing project in July 2016.

2011-2015

• Kunming Longjin Pharmaceutical Co., Ltd. was included in Top 100 Non-public Enterprises of Yunnan Province in 2015.
• Kunming Longjin Pharmaceutical Co., Ltd. was listed on Shenzhen Stock Exchange on March 24, 2015.
• The share prospectus of Kunming Longjin Pharmaceutical Co., Ltd. was pre-disclosed on the website of China Securities Regulatory Commission on May 4, 2014.
• The production line of freeze-drying preparation for injection in the new plant was conferred with the new-version drug GMP certificate by CFDA on November 25, 2013.
• Kunming Longjin Pharmaceutical Co., Ltd. was classified as the leading enterprise cultivating object of strategic emerging industry in Yunnan Province in September 2013.
• The phase I project construction of the new plant was completed, and the production line of freeze-drying preparation for injection passed the new-version GMP field certification on September 14, 2013.

2006-2010

• Kunming Longjin Pharmaceutical formally submitted the application for being listed on SME board of Shenzhen Exchange to China Securities Regulatory Commission, which was accepted by China Securities Regulatory Commission on December 27, 2010.
• The new plant of Kunming Longjin Pharmaceutical in Majinpu was formally commenced for construction on January 27, 2010.
• Kunming Longjin Pharmaceutical passed the GMP re-certification by CFDA for the third time in December 2009.
• The new plant plan was launched and the land of 100 mu (1 mu=0.0667 hectares) was expropriated in Majinpu, Kunming in February, 2009.
• Kunming Longjin Pharmaceutical Co., Ltd. was restructured to a joint-stock company on August 8, 2008.
• The joint-stock company founding assembly was held, and the first board of directors and the first board of supervisors were elected by the shareholder meeting on July 28, 2008.
• Kunming Longjin Pharmaceutical formally launched the listing work and three agencies started providing assistance in September 2007.
• Kunming Longjin Pharmaceutical acquired “Beijing Chuangli Kechuang Medicine Technology Development Co., Ltd.” by 1 in August 2007.
• “Preparation Technology of High-Purity Erigeron Breviscapine Bulk Drug for Injection” was conferred with the invention patent; “Longjin” brand was conferred with Yunnan Famous Brand in 2007.

2001-2005

• Kunming Longjin Pharmaceutical successfully passed the GMP re-certification by CFDA in December 2005.
• Kunming Longjin Pharmaceutical was included into Top 100 Industrial Enterprises of Kunming in 2005.
• Kunming Longjin Pharmaceutical cooperated with Hong Kong Lixing Industry Co., Ltd. to establish the joint venture in January 2003.

1996-2000

• “Breviscapine Freeze-dried Agent for Injection and Preparation Technology” project was conferred with the First Spark Prize of Yunnan Province in March 2000.
• The international advanced lyophilization production line and modern production building were completed in 2000.
• “Breviscapine Freeze-dried Agent for Injection and Preparation Technology” project was conferred with the Scientific and Technological Progress First Prize of Kunming City in December 1999.
• “Longjin Breviscapine Freeze-dried Powder Injection” was conferred with the national key new product certificate in 1999.
• The enterprise started being renovated in GMP and a new production building and a new production line were built in 1998.
• Kunming Longjin Pharmaceutical Co., Ltd. was founded on September 16, 1996.

1991-1995

• Kunming Qunxing Pharmaceutical Factory organized the research, development and manufacturing of the self-selected subject Longjin cigarette position clearing buccal tablet and applied for the patent in 1995.
• In 1994, the company obtained the production approval of breviscapine for longjin injection.
• Kunming Qunxing Pharmaceutical Factory organized the research, development and manufacturing of the self-selected subject thymosin for injection in 1993.
• Longjin Breviscapine Freeze-dried Powder Injection was put into production in 1992.
• The company started the R&D and manufacturing of defibrase for injection and transfer factor for injection in 1991.
• Mr. Fan Xian’e self-raised the fund to found Kunming Qunxing Pharmaceutical Factory with the registered capital RMB 830 thousand in 1991.